Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P472: Efficacy of intravenous ustekinumab re-induction in patients with Crohn’s disease with a loss of response

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Heron*1,2, N. Panaccione3, K. Candido1, T. Bessissow1, A. Bitton1, C. Seow3, R. Panaccione3, W. Afif1

1McGill University Health Centre, Department of Gastroenterology, Montreal, Canada, 2Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada

P473: Cumulative histological inflammation predicts colorectal neoplasia in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

O. V. Yvellez1, V. Rai*1, J. Hart2, J. R. Turner2, K. El Jurdi1, D. T. Rubin1

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, USA, 2Brigham and Women's Hospital, Pathology, Boston, MA, USA

P474: Analysis of UC colectomy rates in pre- and post-biologic era in South-East Scotland

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Jenkinson*1, G. R. Jones1, N. Plevris1, M. Lyons2, K. Kirkwood3, C. Lees1

1Western General Hospital, Gastroenterology, Edinburgh, UK, 2University of Edinburgh, Edinburgh, UK, 3Western General Hospital, Pathology, Edinburgh, UK

P475: Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Facchin*1, A. Buda2, R. Cardin1, R. D'Incà3, F. Zingone3, N. Agbariah1, E. Savarino3

1University of Padua, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, Padova, Italy, 2S.Maria del Prato Hospital,, Department of Oncological Gastrointestinal Surgery, Feltre( BL), Italy, 3University of Padua, Department of Oncological Gastrointestinal Surgery, Padova, Italy

P476: Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Knyazev1, A. Kagramanova1, D. Kulakov*1, M. Zvyaglova1, A. Parfenov1

1Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation

P477: Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, R. Strauss2, H. Zhang2, J. Johanns2, P. Szapary2, C. Marano2, S. Danese3

1University of California San Diego, La Jolla, USA, 2Janssen Research and Development, LLC, Spring House, USA, 3Humanitas Research Hospital, Milan, Italy

P478: Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Van den Berghe*1, B. Verstockt2,3, S. Tops1, M. Ferrante2,3, S. Vermeire2,3, A. Gils1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P479: Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies

ECCO '19 Copenhagen

Year: 2019
Authors:

G. R. Lichtenstein1, G. T. Moore*2,3, A. Soonasra4, C. I. Nduaka4, K. Kwok5, L. Wang6, N. Lawendy4, G. Chan4, C. Su4, E. V. Loftus Jr.7

1University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, PA, USA, 2Monash Health, Department of Gastroenterology, Melbourne, VIC, Australia, 3Monash University, School of Clinical Sciences at Monash Health, Melbourne, VIC, Australia, 4Pfizer Inc., Collegeville, PA, USA, 5Pfizer Inc., New York, NY, USA, 6Pfizer Inc., Groton, CT, USA, 7Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, MN, USA

P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ichim*1, A. Dimitriu1, C. Gheorghe1, M. Diculescu1, B. Mateescu2, C. Cijevschi Prelipcean3, L. Gheorghe1

1Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania, 2Colentina Hospital, Bucharest, Romania, 3‘Saint Spiridon’ Hospital, Iasi, Romania

P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre

ECCO '19 Copenhagen

Year: 2019
Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

1Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal

P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Ye*1, M. Chen2, X. Gao3, K. Wu4, Z. Ran5, H. Yang6, Z. Liu7, Q. Cao8

1Xiasha Branch of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Gastroenterology, Hangzhou, China, 2The First Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China, 3The Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China, 4Xijing Hospital of The Fourth Military Medical University, Gastroenterology, Xi’an, China, 5Renji Hospital, School of Medicine, Shanghai Jiaotong University, Gastroenterology, Shanghai, China, 6Peking Union Medical College Hospital, Gastroenterology, Beijing, China, 7The Tenth People's Hospital Affiliated to Tongji University, Gastroenterology, Shanghai, China, 8Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Gastroenterology, Hangzhou, China

P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Yamamoto1, T. Iida2, K. Ikeya2, M. Kato2, A. Matsuura2, S. Tamura3, R. Takano3, S. Tani4, S. Osawa4, K. Sugimoto3, T. Shimoyama*1, H. Hanai2

1Yokkaichi Hazu Medical Centre, IBD Centre, Yokkaichi, Japan, 2Hamamatsu South Hospital, Center for Gastroenterology and Inflammatory Bowel Disease Research, Hamamastu, Japan, 3Hamamatsu University School of Medicine, First Department of Medicine, Hamamatsu, Japan, 4Hamamatsu University School of Medicine, Department of Endoscopic and Photodynamic Medicine, Hamamatsu, Japan

P484: Hepatitis B vaccination in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Cortez Pinto*1, J. Castela1, J. Moleiro1, J. Pereira da Silva1, I. Rosa1, A. Dias Pereira1

1Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Gastroenterology, Lisboa, Portugal

P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Vande Casteele*1,2, V. Jairath2,3,4, J. Jeyarajah2, P. S. Dulai1,2, S. Singh1, B. G. Feagan2,3,4, W. J. Sandborn1,2

1University of California San Diego, Department of Medicine, La Jolla, USA, 2Robarts Clinical Trials, Inc., London, Canada, 3University of Western Ontario, Medicine, London, Canada, 4University of Western Ontario, Epidemiology and Biostatistics, London, Canada

P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Sousa*1, A. Ponte1, J. Rodrigues1, J. Silva1, C. Gomes1, A. Rodrigues1, A. P. Silva1, J. Carvalho1

1Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal

P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Pudilova1, M. Kolar1, D. Duricova*1, K. Malickova1,2, V. Hruba1, N. Machkova1, R. Vanickova1, K. Mitrova1, M. Lukas1, M. Vasatko1, M. Lukas1, M. Bortlik1,3,4

1ISCARE IVF, a.s., Clinical and Research Centre for IBD, Prague, Czech Republic, 2General University Hospital and First Faculty of Medicine, Charles University, Institute of Medical Biochemistry and Laboratory Medicine, Prague, Czech Republic, 3First Faculty of Medicine, Charles University and Military University Hospital, Department of Internal Medicine, Prague, Czech Republic, 4First Faculty of Medicine, Charles University, Institute of Pharmacology, Prague, Czech Republic

P488: Perianal Crohn's disease in the biological era

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Pires*1, A. Carvalho1, D. Martins1, E. Cancela1, A. Silva1, P. Ministro1

1Centro Hospitalar Tondela Viseu, Gastrenterologia, Viseu, Portugal

P489: Defective anti-microbial peptides expression in Crohn’s disease mucosa can be reversed by strengthening IL-22 signalling

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Fantou*1,2, J. Martin1,2, A. Jarry3, A. Bourreille4,5, R. Josien1,2

1Centre de Recherche en Transplantation et Immunologie UMR 1064, Inserm, Université de Nantes, CHU Nantes, 44000, Nantes, France, 2Laboratoire d'Immunologie, CHU Nantes, 44000, Nantes, France, 3CRCINA, INSERM, Université d'Angers, Université de Nantes, 44000, Nantes, France, 4Institut des Maladies de l’Appareil Digestif (IMAD), CHU Nantes, 44000, Nantes, France, 5UMR 1235, Neuropathies entériques et pathologies digestives, Université de Nantes,, 44000, Nantes, France

P490: A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Rosario*1, D. Polhamus2, C. Chen1, W. Sun1, N. Dirks2

1Takeda Pharmaceuticals, Cambridge, USA, 2Metrum Research Group, Tariffville, USA

P491: INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Zmora*1, J. Panés2, C. Drohan3, J. M. Khalid4, S. Campbell-Hill4, C. Agboton5

1Assaf Harofeh Medical Center, Tel Aviv University, Department of Surgery, Tel Aviv, Israel, 2Hospital Clínic de Barcelona, Gastroenterology Department, Barcelona, Spain, 3Patient Advisor, County Dublin, Ireland, 4Takeda Development Centre, London, UK, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland